China’s Kelun Expects ADC Strategy To Deliver By Balancing Safety, Efficacy

Major Merck Deals

 
• By Dexter Jie Yan
  
drug design rationale
Kelun says ADC programs at center of Merck deals balance safety and efficacy. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia